Topic

cannabidiol

3 petitions

Started 3 months ago

Petition to Iowa Department of Public Health

Iowans Right to Use Cannabidiol for Ulcerative Colitis

In 2017, Iowa expanded their medical cannabidiol (CBD) laws, and by June 1st, 2019, there will be 5 locations serving patients with the following diseases: Cancer (with severe or chronic pain, nausea or severe vomiting, cachexia or severe wasting); Multiple sclerosis with severe and persistent muscle spasms; Seizures; AIDS or HIV (as defined in Iowa Code, section 141A.1); Crohn’s disease; Amyotrophic lateral sclerosis (ALS); Any terminal illness, with a probable life expectancy of under one year (if the illness or its treatment produces one or more of the following: severe or chronic pain, nausea or severe vomiting; cachexia or severe wasting); Parkinson’s disease; and Untreatable pain. Unfortunately, ulcerative colitis is not covered under current Iowa's Medical CBD laws. Ulcerative colitis is an autoimmune disease that causes inflammation in the rectum and colon. Recent studies demonstrated that cannabidiol reduced symptoms of ulcerative colitis and intestinal inflammation via the neuroimmune axis. Similarly, this is why Crohn's disease is on the list of approved diseases. Please sign this petition if you are in support of Iowan's right to CDB treatment for ulcerative colitis. Your signatures will be sent with a petition application to the Iowa Department of Public Health, Office of Medical Cannabidiol. Thank you. ReferencesA Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.Inflamm Bowel Dis. 2018 Mar 19;24(4):714-724. doi: 10.1093/ibd/izy002.Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.PLoS One. 2011;6(12):e28159. doi: 10.1371/journal.pone.0028159. Epub 2011 Dec 6.  

Dylan Pieper
70 supporters
Started 2 years ago

Petition to Deborah A. Armstrong, Bill B. O'Neill

Stop HB 351 & SB 365: Defining and Scheduling Cannabidiol

Senator Bill O'Neill and Representative Deborah Armstrong have both recently proposed bills which attempt to place Cannabidiol (CBD) under the New Mexico Controlled Substances Act, listing CBD as a Schedule V substance and would only allow pharmaceutical companies with FDA approval to produce CBD products. As of today, there is only one company that has FDA approval, creating a temporary monopoly on CBD that would restrict access to full spectrum extracts in New Mexico. With this bill enacted anyone who seeks the aid of CBD will have limited choices on what they can be prescribed and what they can use for their health. Epidiolex, a prescription CBD medicine currently going through clinical trials, is composed of a Cannabidiol isolate. Recent trials with Epidiolex use on children and young adults who suffer from epilepsy showed 50% reduction in seizures for 39% of patients. While this study is promising, other research has shown better results with epilepsy patients who use Cannabidiol products that are whole plant extracts rather than isolates. The Realm of Caring Foundation conducted a study using the whole plant extract Charlotte’s Web with a group of 107 children with epilepsy, and found that 60% of the patients saw at least a 50% decrease in seizures, while 10% of patients reported being seizure free. It is important that patients and consumers have the ability to choose where their Cannabidiol comes from, so that they have the power to decide what will give them the relief they need. Choice is a powerful determining factor in the Cannabinoid industry. For a substance to be classified as a Schedule V substance under the Controlled Substances Act, it must meet the following guidelines: (A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV. (B) The drug or other substance has a currently accepted medical use in treatment in the United States. (C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV. Now let's see how Cannabidiol compares to these guidelines (A) Cannabidiol does have a low potential for abuse, as it is not a psychoactive chemical. (B) Cannabidiol is known to help with a large variety of ailments, which are recognized by many members of the medical community. (C) Abuse of CBD, if at all possible, does not lead to dependence to the substance, and some studies even show CBD benefiting those who are dependent on other substances. Cannabidiol has a wide range of benefits and is used for a variety of reasons, such as anxiety, sleep aid, pain relief, epilepsy, muscle spasms and much more. However, if it becomes required to have a prescription for CBD, some of these ailments may not be considered severe enough to be considered for a Cannabidiol prescription. This bill will hurt those seeking relief more than anyone else. To stop these bills from going through New Mexico's congress, please sign this petition. Please contact Senator O'Neill and Representative Armstrong to voice your concern Senator O’Neill: 505-986-4260 Representative Armstrong: 505-986-4840

Thomas Martinez
825 supporters